| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3386f5906dc1bdc9c934203594712c66 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-0102 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-0102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate |
2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07dbb8b9d2282e24786204cdf9ecae4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_648cfda9e5d53c1ca09075997fab590c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cefa0202fefc53651015b57589379b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa2df23f77afaf647a3ad70f86a7cce3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17d807fb9c23789c83acff2e20aa4f4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb3af3422b59014db973ff133d6f230c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b9e1f1ebc978b270708722f916741ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_087aac357023c5f807206181a345f748 |
| publicationDate |
2018-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018213340-A1 |
| titleOfInvention |
Recombinant human acid alpha-glucosidase |
| abstract |
Provided are a recombinant acid α-glucosidase and pharmaceutical composition comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa. Also provided herein are methods of producing, purifying, and formulating the recombinant acid α-glucosidase or pharmaceutical composition for administration to a subject and methods of treating a disease or disorder such as Pompe disease using the recombinant acid α-glucosidase or pharmaceutical composition. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208458-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021170831-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3871687-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022174037-A1 |
| priorityDate |
2017-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |